All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q3 report for GALDERMA LABORATORIES, L.P. on October 20, 2026, reporting $60,000 in lobbying income.

Lobbying for GALDERMA LABORATORIES, L.P. · Pharmaceutical company specializing in dermatological treatments.

All filings by DLA PIPER LLP (US) · Everything GALDERMA LABORATORIES, L.P. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.

Trade (domestic/foreign)

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.